GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Abliva AB (OSTO:ABLI) » Definitions » Loans Receivable

Abliva AB (OSTO:ABLI) Loans Receivable : kr0.00 Mil (As of Mar. 2024)


View and export this data going back to 2008. Start your Free Trial

What is Abliva AB Loans Receivable?

Abliva AB's Loans Receivable for the quarter that ended in Mar. 2024 was kr0.00 Mil.


Abliva AB Loans Receivable Historical Data

The historical data trend for Abliva AB's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Abliva AB Loans Receivable Chart

Abliva AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Abliva AB Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Abliva AB Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Abliva AB Loans Receivable Related Terms

Thank you for viewing the detailed overview of Abliva AB's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Abliva AB (OSTO:ABLI) Business Description

Traded in Other Exchanges
Address
Scheeletorget 1, Medicon Village, Lund, SWE, 223 81
Abliva AB is a Swedish company that is active in pharmaceutical development. It develops medicines for the treatment of primary mitochondrial diseases. These congenital, rare, and often very severe diseases occur when the cell's energy provider, the mitochondria, does not function properly. The portfolio includes projects at different stages and ranges from the early discovery phase to the clinical phase.

Abliva AB (OSTO:ABLI) Headlines

No Headlines